Friday 6 November 2026 Export INSM’s income statement to Excel — free account

Insmed, Inc.

INSM Healthcare Biotechnology

Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.

Revenue: +268.4%
EPS: +73.8%
Free cash flow: +81.1%
Total debt: +0.27%

Quarter to September 2026, against a year earlier

Revenue growth 5 yrs

112.52 3.76 +3.46%

Follow INSM

Alert me

Market cap: $23.9B
P/E: 0.0×
Fwd P/E: −64.6×
Dividend yield: —
F-score: 4/9
Altman Z: 9.29
Beneish M: −1.90
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Insmed, Inc. (INSM) Debt to equity

Alert me on Debt to equity

Insmed, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.8×, up 0.0× from fiscal 2025 (0.8×). Over the past ten years it has ranged from −3.6× (fiscal 2023) to 13.1× (fiscal 2022); the current reading is higher than 45% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INSM/debt-to-equity" width="100%" height="360" style="border:0" loading="lazy" title="Insmed, Inc. debt to equity, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INSM/metrics/debt-to-equity">Insmed, Inc. (INSM) debt to equity — stockrow.com</a></p>

Period	Debt to equity	Change
FY2025	0.8×	(80.76%)
FY2024	4.0×	—
FY2023	−3.6×	—
FY2022	13.1×	828.18%
FY2021	1.4×	5.19%
FY2020	1.3×	(0.99%)
FY2019	1.4×	(10.63%)
FY2018	1.5×	887.65%
FY2017	0.2×	(56.61%)
FY2016	0.4×	339.53%

Period	Debt to equity	Change
Sep 2026	0.8×	4.38%
Jun 2026	0.7×	(6.88%)
Mar 2026	0.8×	4.91%
Dec 2025	0.8×	28.05%
43 more quarters	Free account

Against its own ten years

Low −3.6× High 13.1×

Ten-year median 1.3×

Current reading's percentile 45

Company	Debt to equity
BBIO BridgeBio Pharma, Inc. compare	−1.2×
ROIV Roivant Sciences Ltd. compare	0.0×
EXEL Exelixis, Inc. compare	0.0×
INCY Incyte Corporation compare	0.0×
BNTX BioNTech SE Sponsored ADR compare	0.0×
ALNY Alnylam Pharmaceuticals, Inc. compare	0.3×
ASND Ascendis Pharma A/S compare	0.3×
INSM Insmed, Inc.	0.8×
GMAB Genmab A/S Sponsored ADR compare	0.9×
Biotechnology industry median	0.0×
Healthcare sector median	0.0×
Market median	0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

Insmed, Inc. (INSM) Debt to equity

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on INSM

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on INSM

Stockrow Weekly